-The Hindu Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...
More »SEARCH RESULT
Total Matching Records found : 223
YK Sapru, founder chairperson of Cancer Patients Aid Association (CPAA) interviewed by Sushmi Dey
-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....
More »Supreme Court rules for cheap cancer drug -Subodh Varma
-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »Novartis order may force pharma MNCs to change
-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...
More »Novartis case may make foreign firms more wary of Indian drugs market-Ravi Ananthanarayanan
-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...
More »
